146.47
price down icon0.62%   -0.92
after-market Dopo l'orario di chiusura: 145.70 -0.77 -0.53%
loading
Precedente Chiudi:
$147.39
Aprire:
$145.64
Volume 24 ore:
5.51M
Relative Volume:
3.76
Capitalizzazione di mercato:
$21.34B
Reddito:
$9.61B
Utile/perdita netta:
$1.62B
Rapporto P/E:
7.9733
EPS:
18.37
Flusso di cassa netto:
$1.77B
1 W Prestazione:
-2.37%
1M Prestazione:
-6.11%
6M Prestazione:
-35.07%
1 anno Prestazione:
-40.98%
Intervallo 1D:
Value
$145.07
$147.85
Intervallo di 1 settimana:
Value
$145.07
$154.24
Portata 52W:
Value
$145.07
$268.30

Biogen Inc Stock (BIIB) Company Profile

Name
Nome
Biogen Inc
Name
Telefono
(781) 464-2000
Name
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Name
Dipendente
7,570
Name
Cinguettio
@biogen
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
BIIB's Discussions on Twitter

Confronta BIIB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
BIIB
Biogen Inc
146.47 21.34B 9.61B 1.62B 1.77B 11.07
Drug Manufacturers - General icon
LLY
Lilly Eli Co
767.76 690.46B 40.86B 8.37B -2.28B 9.25
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
85.00 377.54B 39.36B 13.79B 9.83B 3.086
Drug Manufacturers - General icon
JNJ
Johnson Johnson
144.47 347.83B 87.70B 14.68B 19.03B 6.05
Drug Manufacturers - General icon
ABBV
Abbvie Inc
175.58 310.27B 55.53B 5.12B 15.62B 2.88
Drug Manufacturers - General icon
MRK
Merck Co Inc
98.05 248.03B 63.17B 12.15B 14.84B 4.77

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-16 Downgrade Stifel Buy → Hold
2024-12-10 Ripresa BofA Securities Neutral
2024-12-09 Downgrade Jefferies Buy → Hold
2024-11-18 Downgrade Needham Buy → Hold
2024-11-15 Iniziato Wolfe Research Peer Perform
2024-11-14 Iniziato Citigroup Neutral
2024-10-31 Downgrade Morgan Stanley Overweight → Equal-Weight
2024-10-10 Ripresa Raymond James Mkt Perform
2024-02-14 Reiterato Needham Buy
2024-02-14 Downgrade Wells Fargo Overweight → Equal Weight
2024-01-24 Downgrade UBS Buy → Neutral
2023-12-20 Ripresa Cantor Fitzgerald Overweight
2023-12-07 Aggiornamento Raymond James Mkt Perform → Outperform
2023-09-06 Iniziato HSBC Securities Buy
2023-07-27 Iniziato Scotiabank Sector Outperform
2023-07-24 Reiterato UBS Buy
2023-05-01 Aggiornamento Guggenheim Neutral → Buy
2023-04-17 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-26 Aggiornamento Goldman Neutral → Buy
2022-10-13 Aggiornamento Stifel Hold → Buy
2022-10-07 Aggiornamento Argus Hold → Buy
2022-09-28 Aggiornamento BMO Capital Markets Market Perform → Outperform
2022-09-28 Aggiornamento Mizuho Neutral → Buy
2022-09-28 Aggiornamento Robert W. Baird Neutral → Outperform
2022-04-18 Aggiornamento Wells Fargo Equal Weight → Overweight
2022-03-08 Downgrade Stifel Buy → Hold
2022-03-03 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2022-02-04 Downgrade BMO Capital Markets Outperform → Market Perform
2022-02-04 Reiterato Barclays Equal Weight
2022-02-04 Reiterato BofA Securities Neutral
2022-02-04 Reiterato Cowen Outperform
2022-02-04 Reiterato Morgan Stanley Overweight
2022-02-04 Reiterato Needham Buy
2022-02-04 Reiterato Oppenheimer Outperform
2022-02-04 Reiterato RBC Capital Mkts Sector Perform
2022-02-04 Reiterato Robert W. Baird Neutral
2022-02-04 Reiterato Wedbush Neutral
2022-02-04 Reiterato Wells Fargo Equal Weight
2022-02-04 Reiterato Wolfe Research Peer Perform
2022-01-13 Downgrade Guggenheim Buy → Neutral
2022-01-12 Downgrade Piper Sandler Overweight → Neutral
2021-12-10 Ripresa Raymond James Mkt Perform
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-12-06 Iniziato Goldman Neutral
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-09-23 Iniziato Needham Buy
2021-06-18 Aggiornamento Piper Sandler Neutral → Overweight
2021-06-14 Reiterato Truist Buy
2021-06-11 Aggiornamento Bernstein Mkt Perform → Outperform
2021-06-10 Aggiornamento UBS Neutral → Buy
2021-06-08 Aggiornamento Atlantic Equities Underweight → Neutral
2021-06-08 Reiterato Barclays Equal Weight
2021-06-08 Aggiornamento Citigroup Sell → Neutral
2021-06-08 Reiterato H.C. Wainwright Buy
2021-06-08 Reiterato Jefferies Buy
2021-06-08 Reiterato Morgan Stanley Overweight
2021-06-08 Reiterato RBC Capital Mkts Sector Perform
2021-06-08 Aggiornamento Robert W. Baird Underperform → Neutral
2021-06-08 Reiterato Stifel Buy
2021-06-08 Aggiornamento William Blair Mkt Perform → Outperform
2021-06-07 Aggiornamento BofA Securities Underperform → Neutral
2021-06-07 Aggiornamento Cowen Market Perform → Outperform
2021-06-07 Aggiornamento Raymond James Underperform → Mkt Perform
2021-02-05 Downgrade DZ Bank Buy → Hold
2021-01-29 Aggiornamento Stifel Hold → Buy
2020-11-10 Aggiornamento DZ Bank Hold → Buy
2020-11-09 Downgrade Atlantic Equities Neutral → Underweight
2020-11-09 Downgrade BofA Securities Neutral → Underperform
2020-11-09 Downgrade Cowen Outperform → Market Perform
2020-11-09 Reiterato H.C. Wainwright Buy
2020-11-04 Aggiornamento BofA Securities Underperform → Neutral
2020-11-04 Aggiornamento Jefferies Hold → Buy
2020-11-04 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-10-28 Iniziato UBS Neutral
2020-07-27 Aggiornamento Morgan Stanley Underweight → Overweight
2020-06-22 Downgrade Barclays Overweight → Equal Weight
2020-06-22 Reiterato RBC Capital Mkts Sector Perform
2020-06-09 Downgrade Bernstein Outperform → Mkt Perform
2020-04-23 Downgrade Citigroup Neutral → Sell
2020-04-23 Downgrade Raymond James Mkt Perform → Underperform
2020-03-31 Iniziato Wolfe Research Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-01-27 Aggiornamento Canaccord Genuity Hold → Buy
2019-12-13 Aggiornamento Credit Suisse Underperform → Neutral
2019-12-02 Downgrade Robert W. Baird Neutral → Underperform
Mostra tutto

Biogen Inc Borsa (BIIB) Ultime notizie

pulisher
Dec 20, 2024

Biogen (NASDAQ:BIIB) Upgraded by StockNews.com to Strong-Buy Rating - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

BMO cuts rating on Merck and Biogen, on lack of near term catalyst - MSN

Dec 20, 2024
pulisher
Dec 20, 2024

This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga

Dec 20, 2024
pulisher
Dec 20, 2024

Biogen in talks to move to MIT's Volpe development, sources say - NBC Boston

Dec 20, 2024
pulisher
Dec 20, 2024

Biogen (NASDAQ:BIIB) Downgraded to Market Perform Rating by BMO Capital Markets - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Biogen stock under pressure as rare disease growth lags, says BMO - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

Neuroimmunology Drugs Market Key Players AnalysisAB Science - openPR

Dec 20, 2024
pulisher
Dec 19, 2024

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

Dec 19, 2024
pulisher
Dec 19, 2024

Recombinant DNA Technology Market Expected to Reach Huge Growth - openPR

Dec 19, 2024
pulisher
Dec 19, 2024

Biogen (NASDAQ:BIIB) Sets New 52-Week LowHere's Why - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Coagulation Factor Deficiency Market Key Players AnalysisPfizer Inc, Grifols, Biogen, Octapharma, Baxter. - openPR

Dec 19, 2024
pulisher
Dec 18, 2024

Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Dec 18, 2024
pulisher
Dec 18, 2024

Eli Lilly's Alzheimer's treatment approved in China - Reuters

Dec 18, 2024
pulisher
Dec 18, 2024

Eli Lilly's Alzheimer's treatment approved in China (Dec. 17) - Yahoo Canada Finance

Dec 18, 2024
pulisher
Dec 18, 2024

Biogen's SWOT analysis: stock outlook amid alzheimer's drug launch and pipeline shifts - Investing.com

Dec 18, 2024
pulisher
Dec 18, 2024

Multiple Sclerosis Therapeutics Market to See Booming Growth - openPR

Dec 18, 2024
pulisher
Dec 18, 2024

Gene Therapy Market Key Players AnalysisNovartis Ag, Biogen - openPR

Dec 18, 2024
pulisher
Dec 17, 2024

Biogen Stock: Is BIIB Underperforming the Healthcare Sector? - Nasdaq

Dec 17, 2024
pulisher
Dec 17, 2024

Biogen Stock: Is BIIB Underperforming The Healthcare Sector? - Barchart

Dec 17, 2024
pulisher
Dec 17, 2024

Why are Biogen, Pfizer, and GSK Trading at a Discount? - Baystreet.ca

Dec 17, 2024
pulisher
Dec 17, 2024

Franklin Resources Inc. Sells 13,723 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Dec 17, 2024
pulisher
Dec 17, 2024

Biogen downgraded to Hold by Stifelslower progress than expected - Marketscreener.com

Dec 17, 2024
pulisher
Dec 17, 2024

Spinal Muscular Atrophy Market Overall Study Report 2024-2031 | - openPR

Dec 17, 2024
pulisher
Dec 16, 2024

Stifel downgrades Biogen on slow Alzheimer’s drug launch, uncertainty ahead - MSN

Dec 16, 2024
pulisher
Dec 16, 2024

Biogen Inc. stock rises Monday, still underperforms market - MarketWatch

Dec 16, 2024
pulisher
Dec 16, 2024

Netflix, Ford, Biogen: Trending tickers - Yahoo Finance

Dec 16, 2024
pulisher
Dec 16, 2024

Biogen (NASDAQ:BIIB) Cut to "Hold" at Stifel Nicolaus - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Analyst recommendations: Biogen, Broadcom, Exxon, UnitedHealth, Tesla, Twilio... - Marketscreener.com

Dec 16, 2024
pulisher
Dec 16, 2024

World Investment Advisors LLC Acquires Shares of 5,766 Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Ionis Pharmaceuticals, Inc. announced that it expects to receive $624.972654 million in funding from Biogen Inc. - Marketscreener.com

Dec 16, 2024
pulisher
Dec 15, 2024

Quantinno Capital Management LP Lowers Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Dec 15, 2024
pulisher
Dec 14, 2024

Biogen (NASDAQ:BIIB) Hits New 12-Month LowShould You Sell? - MarketBeat

Dec 14, 2024
pulisher
Dec 14, 2024

Oddo BHF Asset Management Sas Purchases Shares of 7,136 Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Dec 14, 2024
pulisher
Dec 13, 2024

CMS Tells MA Plans Not To Exclude Biogen’s Qalsody Because Of Accelerated Approval - Citeline

Dec 13, 2024
pulisher
Dec 13, 2024

Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch

Dec 13, 2024
pulisher
Dec 13, 2024

CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug - BioPharma Dive

Dec 13, 2024
pulisher
Dec 13, 2024

Biogen Inc. (NASDAQ:BIIB) Shares Bought by Inspire Trust Co. N.A. - MarketBeat

Dec 13, 2024
pulisher
Dec 12, 2024

Biogen ALS drug needs to be covered by MA plans, CMS says - MSN

Dec 12, 2024
pulisher
Dec 12, 2024

Private Medicare plans must cover Biogen's ALS drug, US agency says - Reuters

Dec 12, 2024
pulisher
Dec 12, 2024

Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Dec 12, 2024
pulisher
Dec 12, 2024

Kidney Disease - Biogen

Dec 12, 2024
pulisher
Dec 12, 2024

Biogen's SWOT analysis: stock faces leqembi launch hurdles amid pipeline shifts - Investing.com

Dec 12, 2024
pulisher
Dec 12, 2024

Is Biogen Inc.'s (NASDAQ:BIIB) Stock Price Struggling As A Result Of Its Mixed Financials? - Yahoo Finance

Dec 12, 2024
pulisher
Dec 12, 2024

Saratoga Research & Investment Management Sells 7,071 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

Virtu Financial LLC Invests $4.11 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

The Escalator: Biogen, Accent Therapeutics, Xira Therapeutics and more - MM+M Online

Dec 12, 2024
pulisher
Dec 12, 2024

Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Geode Capital Management LLC - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

Public Employees Retirement System of Ohio Has $10.26 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

Nomura Asset Management Co. Ltd. Has $9.56 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

Postpartum Depression Treatment Market Size, Trends, Growth, - openPR

Dec 12, 2024
pulisher
Dec 11, 2024

Biogen Inc. stock rises Wednesday, still underperforms market - MarketWatch

Dec 11, 2024

Biogen Inc Azioni (BIIB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general BMY
$57.33
price up icon 1.83%
drug_manufacturers_general SNY
$47.71
price up icon 0.44%
$263.38
price up icon 0.84%
drug_manufacturers_general PFE
$26.36
price up icon 2.29%
drug_manufacturers_general NVS
$97.11
price up icon 0.35%
drug_manufacturers_general MRK
$98.05
price down icon 1.48%
Capitalizzazione:     |  Volume (24 ore):